ZIM Laboratories’ arm gets nod to market ‘Azithromycin for Oral Suspension’ in Portugal

23 Jul 2024 Evaluate

ZIM Laboratories’ wholly owned European Subsidiary -- SIA ZIM Laboratories has received Marketing Authorisation (MA) from INFARMED (Portugal) -- Portuguese National Authority of Medicines and Health Products for one of ZIM’s New Innovative Products (NIP) ‘Azithromycin for Oral Suspension 200 mg/5ml’ in Portugal. 

This is the 1st Marketing Authorisation for ZIM for its New Innovative Products for Europe. Azithromycin Oral Suspension is differentiated in taste masked suspension dosage form which benefits patients who have difficulty in swallowing and children who have difficulty with bitter taste. According to IQVIA, the EU market size for this product in 2022 was around $300 million. Additionally, other target markets for ZIM such as SE Asia & Oceania, Latin America and MENA have a combined market size of around $900 million.

ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develops generic pharmaceutical products.


Zim Laboratories Share Price

107.40 4.05 (3.92%)
22-Nov-2024 09:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1772.55
Dr. Reddys Lab 1198.25
Cipla 1466.95
Lupin 2032.15
Zydus Lifesciences 945.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.